Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women - Report - MDSpire
Advertisement
Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women
Clinical Report: GnRH Agonists in Feminizing Hormone Therapy Outcomes
Overview
This study evaluates the metabolic and bone health outcomes of GnRH agonists in adult transgender women undergoing feminizing hormone therapy. Findings indicate that GnRH agonists do not adversely affect metabolic parameters or bone mineral density over a 12-month period.
Background
Gender-affirming hormone therapy (GAHT) is crucial for alleviating gender dysphoria in transgender individuals. Understanding the effects of GAHT on metabolic and bone health is essential, as concerns have been raised regarding potential negative outcomes. This study aims to clarify these effects specifically in adult transgender women receiving GnRH agonists.
Data Highlights
Parameter
Baseline
12 Months
P-value
BMI
-
-
0.14
Fat Mass Index
-
-
0.14
Visceral Adipose Tissue
-
-
0.73
Lean Mass Index
-
-0.66 kg/m2
<0.001
HDL-cholesterol
-
+0.18 mmol/L
<0.001
Low BMD (Z-score < -2.0 SD)
41%
27%
-
BMD at Lumbar Spine
-
+0.03 g/cm2
<0.001
Key Findings
GAHT did not significantly change BMI, fat mass index, or visceral adipose tissue.
Lean mass indices decreased significantly by -0.66 kg/m2 after 12 months of treatment.
The percentage of participants with low BMD decreased from 41% to 27% over 12 months.
BMD at the lumbar spine increased by +0.03 g/cm2, suggesting positive bone health outcomes.
Changes in metabolic outcomes were not significantly associated with estradiol levels.
Clinical Implications
Clinicians can consider GnRH agonists as a safe component of feminizing hormone therapy without significant adverse effects on metabolic or bone health. Regular monitoring of bone density and metabolic parameters remains important to ensure optimal health outcomes for transgender women.
Conclusion
The use of GnRH agonists in feminizing hormone therapy appears to be safe concerning metabolic and bone health outcomes. Continued research and monitoring are essential to further validate these findings.
